相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
J. A. Alberro et al.
LANCET ONCOLOGY (2018)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial
Harry D. Bear et al.
JOURNAL OF SURGICAL ONCOLOGY (2017)
Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making
Hannah Dzimitrowicz et al.
JOURNAL OF ONCOLOGY PRACTICE (2017)
Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer A Systematic Review and Meta-analysis
Laura M. Spring et al.
JAMA ONCOLOGY (2016)
A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score
Denise A. Yardley et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
In the Era of Genomics, Should Tumor Size Be Reconsidered as a Criterion for Neoadjuvant Chemotherapy?
Xavier Pivot et al.
ONCOLOGIST (2015)
Evaluating the 21-gene assay Recurrence ScoreA® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer
Takayuki Ueno et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2014)
Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy
Stefan Glueck et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[ plus ] operable breast cancer
Antonio Llombart-Cussac et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2012)
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition
Masakazu Toi et al.
CANCER SCIENCE (2011)
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Molecular Characterization of Breast Cancer Core Biopsy Specimens by Gene Expression Analysis Using Standardized Quantitative RT-PCR.
J. Anderson et al.
CANCER RESEARCH (2010)
Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain et al.
LANCET ONCOLOGY (2010)
21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients
Sadako Akashi-Tanaka et al.
BREAST (2009)
Improved Surgical Outcomes for Breast Cancer Patients Receiving Neoadjuvant Aromatase Inhibitor Therapy: Results from a Multicenter Phase II Trial
John A. Olson et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2009)
Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer:: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy
Ute E. Krainick-Strobel et al.
BMC CANCER (2008)
Locally advanced and inflammatory breast cancer
Stephen Chia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients
Jenny C. Chang et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy
Sadako Akashi-Tanaka et al.
BREAST (2007)
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer
Vladimir F. Semiglazov et al.
CANCER (2007)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer - The Pre-Operative Arimidex Compared to Tamoxilen (PROAC7) trial
L Cataliotti et al.
CANCER (2006)
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients
Laurel A. Habel et al.
BREAST CANCER RESEARCH (2006)
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer
L Gianni et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
IE Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis
D Mauri et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:: Evidence from a phase III randomized trial
MJ Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
W Eiermann et al.
ANNALS OF ONCOLOGY (2001)
分享论文
